Trial record 1 of 1 for:
VGX-3100 | vin
Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03180684 |
|
Recruitment Status :
Recruiting
First Posted : June 8, 2017
Last Update Posted : June 10, 2019
|
Sponsor:
Inovio Pharmaceuticals
Information provided by (Responsible Party):
Inovio Pharmaceuticals
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
The purpose of this study is to test the safety and efficacy of an investigational immunotherapy VGX-3100, in combination with a study device, to treat women with vulvar HSIL (VIN 2 or VIN 3) associated with HPV types 16 and/or 18. VGX-3100 is being assessed as an alternative to surgery with the potential to clear the underlying HPV infection. For more information visit our study website at: www.VINresearchstudy.com
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Vulvar High Grade Squamous Intraepithelial Lesion (HSIL) Vulvar Dysplasia Vulvar Intraepithelial Neoplasia (VIN) VIN2 VIN3 Pre-cancerous Lesions of the Vulva Human Papillomavirus (HPV) | Biological: VGX-3100 Drug: Imiquimod 5% cream Device: CELLECTRA™ 2000 | Phase 2 |
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 36 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A Phase 2, Randomized, Open Label, Efficacy Study of VGX-3100 Delivered Intramuscularly Followed by Electroporation With CELLECTRA™ 2000 Alone or in Combination With Imiquimod, for the Treatment of HPV-16 and/or HPV-18 Related High Grade Squamous Intraepithelial Lesion (HSIL) of the Vulva |
| Actual Study Start Date : | June 26, 2017 |
| Estimated Primary Completion Date : | August 2020 |
| Estimated Study Completion Date : | September 2021 |
Resource links provided by the National Library of Medicine
Drug Information available for:
Imiquimod
| Arm | Intervention/treatment |
|---|---|
|
Experimental: VGX-3100 + EP
Intramuscular (IM) injections with VGX-3100 followed by EP using the CELLECTRA™ 2000 device on Day 0, Week 4, Week 12 and Week 24.
|
Biological: VGX-3100
One milliliter (1 mL) VGX-3100 will be injected IM and delivered by EP using CELLECTRA™ 2000 on Day 0, Week 4, Week 12 and Week 24. A fifth dose and sixth dose of six mg VGX-3100 may be administered IM with EP per the judgment of the Investigator. Device: CELLECTRA™ 2000 IM injection of VGX-3100 is followed by EP with the CELLECTRA™ 2000 device. |
|
Experimental: VGX-3100 + EP + Imiquimod
IM injections with VGX-3100 followed by EP using the CELLECTRA™ 2000 device on Day 0, Week 4, Week 12 and Week 24. In addition, participants will apply imiquimod 5% cream to the vulvar lesion three times per week for 20 weeks.
|
Biological: VGX-3100
One milliliter (1 mL) VGX-3100 will be injected IM and delivered by EP using CELLECTRA™ 2000 on Day 0, Week 4, Week 12 and Week 24. A fifth dose and sixth dose of six mg VGX-3100 may be administered IM with EP per the judgment of the Investigator. Drug: Imiquimod 5% cream Participants will apply imiquimod 5% cream to the vulvar lesion three times per week for 20 weeks. Device: CELLECTRA™ 2000 IM injection of VGX-3100 is followed by EP with the CELLECTRA™ 2000 device. |
Primary Outcome Measures :
- Percentage of Participants with No Histologic Evidence of Vulvar HSIL and No Evidence of HPV-16 and/or HPV-18 in Vulvar Tissue Samples [ Time Frame: At Week 48 ]
Secondary Outcome Measures :
- Safety: Percentage of Participants with Adverse Events [ Time Frame: From baseline to Week 100 ]
- Percentage of Participants with No Histologic Evidence of Vulvar HSIL [ Time Frame: At Week 48 ]
- Percentage of Participants with No Evidence of HPV-16 and/or HPV-18 in Vulvar Tissue Samples [ Time Frame: At Week 48 ]
- Percentage of Participants with No Evidence of Vulvar HSIL, No Evidence of Vulvar Low Grade Squamous Intraepithelial Lesions (LSIL) (Vulvar Intraepithelial Neoplasia 1 [VIN1]), and No Evidence of Condyloma on Histology [ Time Frame: At Week 48 ]
- Percentage of Participants with No Progression of Vulvar HSIL to Vulvar Cancer [ Time Frame: From baseline to Week 48 ]
- Percent Reduction from Baseline in the Cumulative Surface Area of the Acetowhite Vulvar Lesion(s) [ Time Frame: From baseline to Weeks 48, 74 and 96 ]
- Change from Baseline in Levels of Serum Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations [ Time Frame: From baseline to Weeks 15, 27, 48, 74 and 96 ]
- Change from Baseline in Interferon-Gamma Response Magnitude [ Time Frame: From baseline to Weeks 15, 27, 48, 74 and 96 ]
- Change from Baseline in Flow Cytometry Response Magnitude [ Time Frame: At baseline and Week 27 ]
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Women aged 18 and above;
- Have high grade squamous intraepithelial lesion (HSIL) of the vulva (VIN2 or VIN3) caused by infection with HPV types 16 and/or 18 confirmed at screening visit;
Exclusion Criteria:
- Biopsy-proven differentiated VIN;
- Any previous treatment for vulvar HSIL within 4 weeks prior to screening;
- Allergy to imiquimod 5% cream or to an inactive ingredient in imiquimod 5% cream;
- Pregnant, breastfeeding or considering becoming pregnant within 6 months following the last dose of investigational product;
- Immunosuppression as a result of underlying illness or treatment;
- Significant acute or chronic medical illness.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03180684
Contacts
| Contact: Inovio Call Center | (267) 440-4237 | clinical.trials@inovio.com |
Show 20 Study Locations
Sponsors and Collaborators
Inovio Pharmaceuticals
Investigators
| Study Director: | ShuPing Yang, MD | Inovio Pharmaceuticals |
| Responsible Party: | Inovio Pharmaceuticals |
| ClinicalTrials.gov Identifier: | NCT03180684 History of Changes |
| Other Study ID Numbers: |
HPV-201 |
| First Posted: | June 8, 2017 Key Record Dates |
| Last Update Posted: | June 10, 2019 |
| Last Verified: | June 2019 |
| Studies a U.S. FDA-regulated Drug Product: | Yes | |
| Studies a U.S. FDA-regulated Device Product: | No | |
Keywords provided by Inovio Pharmaceuticals:
|
HPV-16 HPV-18 |
Additional relevant MeSH terms:
|
Carcinoma in Situ Squamous Intraepithelial Lesions of the Cervix Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Uterine Cervical Dysplasia Precancerous Conditions Uterine Cervical Diseases |
Uterine Diseases Genital Diseases, Female Imiquimod Adjuvants, Immunologic Immunologic Factors Physiological Effects of Drugs Antineoplastic Agents Interferon Inducers |